Barchart on Facebook
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Bioxcel Therapeutics Inc (BTAI)

Bioxcel Therapeutics Inc (BTAI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,075,052
  • Shares Outstanding, K 22,355
  • Annual Sales, $ 0 K
  • Annual Income, $ -32,970 K
  • 60-Month Beta 1.64
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 17.59
Trade BTAI with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -0.80
  • Number of Estimates 4
  • High Estimate -0.58
  • Low Estimate -0.93
  • Prior Year -0.57
  • Growth Rate Est. (year over year) -40.35%

Price Performance

See More
Period Period Low Period High Performance
1-Month
41.41 +16.13%
on 09/29/20
55.00 -12.56%
on 10/14/20
+4.95 (+11.47%)
since 09/25/20
3-Month
36.37 +32.22%
on 08/25/20
59.62 -19.34%
on 07/28/20
-13.39 (-21.78%)
since 07/27/20
52-Week
3.76 +1,178.99%
on 11/01/19
71.50 -32.74%
on 07/20/20
+43.51 (+950.00%)
since 10/25/19

Most Recent Stories

More News
BioXcel Therapeutics Receives FDA Clearance of IND for Phase 2 Trial with BXCL501 for the Treatment of Agitation Associated with Delirium

BioXcel Therapeutics, Inc. ("BTI" or "Company") (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology,...

BTAI : 48.09 (+3.46%)
BioXcel Therapeutics to Present at the H.C. Wainwright 22nd Annual Global Investment Conference

BioXcel Therapeutics, Inc. ("BTI" or "Company") (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology,...

BTAI : 48.09 (+3.46%)
BioXcel Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update

SERENITY I & II Phase 3 trials of BXCL501 achieved all primary and secondary endpoints; New Drug Application ("NDA") submission to U.S. Food and Drug Administration ("FDA") planned for Q1 2021

BTAI : 48.09 (+3.46%)
BioXcel Therapeutics to Host Second Quarter 2020 Operating and Financial Results Conference Call and Webcast

BioXcel Therapeutics, Inc. ("BTI" or "Company") (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology,...

BTAI : 48.09 (+3.46%)
BioXcel Therapeutics to Participate in the Canaccord Genuity 40th Annual Growth Conference

BioXcel Therapeutics, Inc. ("BTI" or "Company") (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology,...

BTAI : 48.09 (+3.46%)
BioXcel Therapeutics Announces Appointment of Reina Benabou, M.D., Ph.D., as Chief Development Officer

BioXcel Therapeutics, Inc. ("BTI" or "Company") (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology,...

BTAI : 48.09 (+3.46%)
BioXcel Therapeutics Announces Appointment of William P. Kane as Chief Commercial Officer

BioXcel Therapeutics, Inc. ("BTI" or "Company") (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology,...

AGN : 193.02 (+0.02%)
BTAI : 48.09 (+3.46%)
BioXcel Therapeutics to Participate in Two Upcoming Investor Conferences

BioXcel Therapeutics, Inc. ("BTI" or the "Company") (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology,...

BTAI : 48.09 (+3.46%)
BioXcel Therapeutics Announces First Patient Enrolled in Phase 1b/2 RELEASE Trial of BXCL501 for the Treatment of Opioid Withdrawal Symptoms

BioXcel Therapeutics, Inc. ("BTI" or "Company") (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology,...

BTAI : 48.09 (+3.46%)
BioXcel Therapeutics to Present at the Jefferies Virtual Healthcare Conference

BioXcel Therapeutics, Inc. ("BTI" or the "Company") (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology,...

BTAI : 48.09 (+3.46%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Buy with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

BioXcel Therapeutics Inc. is a clinical stage biopharmaceutical company. It focuses on drug development which utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. The company's product portfolio include BXCL501, a sublingual thin film...

See More

Key Turning Points

2nd Resistance Point 50.09
1st Resistance Point 49.09
Last Price 48.09
1st Support Level 46.55
2nd Support Level 45.01

See More

52-Week High 71.50
Last Price 48.09
Fibonacci 61.8% 45.62
Fibonacci 50% 37.63
Fibonacci 38.2% 29.64
52-Week Low 3.76

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar